07 jun: Bear Stearns, Ex-Executives, Agree to Settle Shareholder Suit for..
07 jun: ECB Foreign Exchange Reference Rates - Jun 07
07-06-2012 14:57:00

PRESS RELEASE: Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Bayer HealthCare Unveils Advances in CT Contrast Dose Management(TM) Solutions

Powerful New Certegra(R) Informatics Workstation launched at SIIM 2012

Intended for U.S. Media Only

PR Newswire

TARRYTOWN, N.Y., June 7, 2012

TARRYTOWN, N.Y., June 7, 2012 /PRNewswire/ -- Bayer Radiology & Interventional announced the introduction of the Certegra(R) Workstation, an informatics-driven, touch--screen hub that enables time savings and improved patient care through a powerful suite of CT Contrast Dose Management(TM) applications and a new P3T(R) 2.0 operating environment. The new Workstation will be presented at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) 2012 June 7 - 12 in Orlando, FL. Following the initial launch in the U.S. and Canada, the Workstation will be rolled out in phases in markets around the world.

The Workstation serves as a single interface for radiology technologists, enabling them to provide improved patient care from study set-up and preparation to administration of the patient's study. It will be the cornerstone of Bayer's industry-first[1] Contrast Dose Management solution and informatics platform. In establishing and uploading the patient's contrast-injection record, the Workstation imports patient data directly from the Modality Work List -- reducing manual entry errors to the patient record.

"Today's technology-driven CT suite demands timely access to reliable contrast-dose records throughout the chain of care," said Anthony Cinalli, vice president of the informatics business at Bayer Radiology & Interventional. "Enabling a single workflow-centralized interface, the Workstation allows for fewer clicks, less manual entry and greater control over the quality and consistency of patient care."

Interfacing with Medrad Stellant(R) CT injection systems, the Workstation's comprehensive suite of software options provides physicians and healthcare professionals instant access to real-time actionable CT contrast data captured at the point of care enabling benefits including:

-- Reduce sub-diagnostic studies, unnecessary rescans and associated

radiation exposure[2] [3],(P3T 2.0 for personalized CT abdominal, cardiac

and pulmonary angiography studies)

-- Enable more complete diagnostic decisions (PACS Outbound Interface)

-- Speed-up radiology report turnaround time and create greater study-volume

bandwidth (RIS and SR Outbound Interfaces)

-- Improve department performance by trending, reporting and analyzing

actionable data with pinpoint accuracy (Informatics Starter Package, and

the Data Analysis and Reporting Tool)

Bayer HealthCare will have the Certegra(R) Workstation on display at its booth at SIIM 2012 (booth #217 - 221).

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

[1] Reference on file.

[2] Presented at Society of Thoracic Radiology (2008) Poster Session; Christopher R. Deible, MD, PhD. Study supported by MEDRAD Inc.

[3] 510(k) FDA clearance number: K082905

SOURCE Bayer HealthCare

/CONTACT: Karen Sutherland, +1-973-487-2113, karen.sutherland@bayer.com or Alicia Cafardi, +1-724-940-8621, alicia.cafardi@bayer.com

/Web site: http://www.bayerhealthcare.com/

(END) Dow Jones Newswires

June 07, 2012 08:57 ET (12:57 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jul
TOPO
Kurshop -  Der findes tusinder af Biotekfirmaer i verden som du kan gå ud og investerer i ! Hvad er ..
17
23 jul
VWS
Jeg sidder og graver mig ind i dette lille interessante skriv:   http://www.power-technology.com/new..
15
20 jul
VELO
Sidder ig gennemlaser tidligere traade og samler her lidt op og vil komme med betragtninger for den ..
13
18 jul
VWS
Pokerchamp - Du er da gået helt fra koncepterne. Din angreb på meddebatørene er da røget helt ud i h..
12
23 jul
PNDORA
Det er helt naturligt, at aktiekursen på et selskab, som er steget meget, svinger kraftigt forud for..
10
11:23
OMXN40
Det bliver/er hverdagskost i alle europæiske lande inden længe.. Men tankevækkende, at terrortruslen..
9
18 jul
VWS
sku vi prøve med en afstemning,ang hvem der er mest ude i hampen Alle dem der hellre vil tro på good..
9
22 jul
VWS
Mon dette forum og skribenterne mon nogensinde bliver så voksent, at vi er undgår dette evindelige b..
8
21 jul
E:VWS
Du kan da umuligt fjerne kernemedarbejdere med 10-30 års erfaring når de ikke engang har haft fabrik..
8
18 jul
GEN
Skønt - det må være det brede fase Ib studie der afføder disse fase III studier:   http://www.clinic..
8

Danske: Bestyrelsesmedlem køber aktier for 236.748 kr.

24-07-2014 16:39:27
Carol Sergeant, der er medlem af bestyrelsen hos Danske Bank, har købt aktier i banken for samlet 236.748 kr. torsdag.Det fremgår af en insidermeddelelse torsda..

Novo: Konkurrent vender tilbage til stærk vækst i insulinsalget

24-07-2014 12:46:29
Amerikanske Eli Lilly, der er en stor konkurrent til Novo Nordisk på insulinmarkedet, leverede tocifret vækst i salget af sit bedst sælgende insulin, Humalog, i..

Aktier/åbning: Danske Bank dominerer efter dukseregnskab

24-07-2014 09:29:28
Danske Bank er der store historie torsdag morgen på det danske aktiemarked, efter at banken har leveret sit bedste kvartalsresultat siden 2007. Det bliver beløn..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/JPMorgan: Kursmål hævet til 490 kr.
2
Danske Q2: Massiv fremgang og opjustering
3
Aktier/tendens: Danske Bank stjæler rampelyset
4
Aktier/åbning: Danske Bank dominerer efter dukseregnskab
5
Novo: Konkurrent vender tilbage til stærk vækst i insulinsalget
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. juli 2014 17:21:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140723.1 - EUROWEB7 - 2014-07-24 17:21:42 - 2014-07-24 17:21:42 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x